The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Rituximab treatment of myasthenia gravis: A systematic review: Rituximab in Myasthenia Gravis
Abstract
Rituximab is a chimeric mouse/human anti-CD20 monoclonal immunoglobulin. We reviewed the efficacy and safety of rituximab in 169 myasthenia gravis (MG) patients from case reports and series. Antibodies to the acetylcholine receptor (AChR) were present in 59% and muscle-specific tyrosine kinase (MuSK) in 34%. Modified Myasthenia Gravis Foundation of America postintervention scale of minimal manifestations (MM) or better occurred in 44%, and combined pharmacologic and chronic stable remission in 27% overall; MM or better was achieved in 72% of MuSK MG and 30% of AChR MG (P < 0.001). Posttreatment relapses decreased more in MuSK MG (P = 0.05). Response predictors were MuSK MG, less severe disease, and younger age at treatment. Among a responder subset, 26% of AChR and 82% of MuSK MG patients showed decreased posttreatment antibody titers. Rituximab was generally well tolerated. Detectable serum rituximab and depleted CD20+ B-cells were observed up to 20 and 16 weeks, respectively, after 4 weekly infusions. Muscle Nerve 56: 185–196, 2017
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Myasthenia gravis: Recommendations for clinical research standards
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000) · Neurology · doi:10.1212/wnl.55.1.16 · Cited by 1,651
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
International consensus guidance for management of myasthenia gravis: Executive summary
Sanders, D. B., Wolfe, G. I., Benatar, M., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N., Massey, J. M., Melms, A., Murai, H., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002790 · Cited by 1,212
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001) · Nature Medicine · doi:10.1038/85520 · Cited by 1,183
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Randomized Trial of Thymectomy in Myasthenia Gravis
Wolfe, G. I., Kaminski, H. J., Aban, I., Minisman, G., Kuo, H., Marx, A., Ströbel, P., Mazia, C. G., Oger, J. J.-F., Cea, G., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602489 · Cited by 1,011
Self-citationEfficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213277 · Cited by 728
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 625
Berinstein, N. L., Grillo-López, A. J., White, C. A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., & Shen, D. (1998) · Annals of Oncology · doi:10.1023/a:1008416911099 · Cited by 526
Iijima, K., Sako, M., Nozu, K., Mori, R., Tuchida, N., Kamei, K., Miura, K., Aya, K., Nakanishi, K., Ohtomo, Y., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60541-9 · Cited by 451
Reliability Testing of the Quantitative Myasthenia Gravis Scorea
BAROHN, R. J., McINTIRE, D., HERBELIN, L., WOLFE, G. I., NATIONS, S., & BRYAN, W. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11015.x · Cited by 417
Long-lasting treatment effect of rituximab in MuSK myasthenia
Díaz-Manera, J., Martínez-Hernández, E., Querol, L., Klooster, R., Rojas-García, R., Suárez-Calvet, X., Muñoz-Blanco, J. L., Mazia, C., Straasheijm, K. R., Gallardo, E., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182407982 · Cited by 346
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
Sanders, D. B., Hart, I. K., Mantegazza, R., Shukla, S. S., Siddiqi, Z. A., De Baets, M. H. V., Melms, A., Nicolle, M. W., Solomons, N., & Richman, D. P. (2008) · Neurology · doi:10.1212/01.wnl.0000312374.95186.cc · Cited by 318
A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis
The Muscle Study Group (2008) · Neurology · doi:10.1212/01.wnl.0000312373.67493.7f · Cited by 225
Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S., Tsai, D., Pullman-Mooar, S., Barnack, F., Striebich, C., Looney, R. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083162 · Cited by 209
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens
Wang, H., Liu, C., Li, Y., & Huang, Y. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2116 · Cited by 175
Response of patients with refractory myasthenia gravis to rituximab: a retrospective study
Nowak, R. J., DiCapua, D. B., Zebardast, N., & Goldstein, J. M. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611411503 · Cited by 158
Response to Therapy in Myasthenia Gravis with Anti‐MuSK Antibodies
Evoli, A., Bianchi, M. R., Riso, R., Minicuci, G. M., Batocchi, A. P., Servidei, S., Scuderi, F., & Bartoccioni, E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1405.012 · Cited by 158
Treatment-Refractory Myasthenia Gravis
Silvestri, N. J., & Wolfe, G. I. (2014) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000034 · Cited by 151
白川, 佳., Agarwal, S., Yin, M., Ren, S., Li, N. F., Shaw, T. M., & Davies, B. E. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007305297 · Cited by 149
Clinical characteristics of refractory myasthenia gravis patients.
Suh, J., Goldstein, J. M., & Nowak, R. J. (2013) · PubMed · Cited by 143
Pharmacokinetics of rituximab and its clinical use: Thought for the best use?
Cartron, G., Blasco, H., Paintaud, G., Watier, H., & Guellec, C. B. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.09.004 · Cited by 127
Sanders, D. B., Burns, T. M., Cutter, G., Massey, J. M., Juel, V. C., Hobson‐Webb, L. D., & The Muscle Study Group (2013) · Muscle & Nerve · doi:10.1002/mus.23944 · Cited by 119
McDonald, V., Manns, K., Mackie, I. J., Machin, S. J., & Scully, M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03818.x · Cited by 109
Pharmacokinetic Behavior of Rituximab
Regazzi, M. B., Iacona, I., Avanzini, M. A., Arcaini, L., Merlini, G., Perfetti, V., Zaja, F. F., Montagna, M., Morra, E., & Lazzarino, M. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000184162.60197.c1 · Cited by 92
Sun, F., Ladha, S. S., Yang, L., Liu, Q., Shi, S. X.-Y., Su, N., Bomprezzi, R., & Shi, F. (2013) · Muscle & Nerve · doi:10.1002/mus.23951 · Cited by 89
Guptill, J. T., Soni, M., & Meriggioli, M. N. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0398-y · Cited by 86
The role of rituximab in adults with warm antibody autoimmune hemolytic anemia
Dierickx, D., Kentos, A., & Delannoy, A. (2015) · Blood · doi:10.1182/blood-2015-01-588392 · Cited by 80
Maintenance immunosuppression in myasthenia gravis
Feldman, L. M., & Li, Y. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.08.057 · Cited by 72
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis
Guptill, J. T., Yi, J. S., Sanders, D. B., Guidon, A. C., Juel, V. C., Massey, J. M., Howard, J. F., Scuderi, F., Bartoccioni, E., Evoli, A., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000077 · Cited by 68
Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
Alexopoulos, H., Biba, A., & Dalakas, M. C. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0402-6 · Cited by 33
Rituximab for Non‐Hodgkin's Lymphoma: A Story of Rapid Success in Translation
Harrison, A. M., Thalji, N. M., Greenberg, A. J., Tapia, C. J., & Windebank, A. J. (2013) · Clinical and Translational Science · doi:10.1111/cts.12111 · Cited by 32
Lu, T., Jonsdottir, T., van Vollenhoven, R., & Isenberg, D. A. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091124 · Cited by 30
Rezania, K., Soliven, B. C., Baron, J. M., Lin, H. H., Penumalli, V., & van Besien, K. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.615426 · Cited by 29
Myocardial infarction after rituximab infusion
Renard, D., Cornillet, L., & Castelnovo, G. (2013) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.03.014 · Cited by 24
Vermeer, N. S., Straus, S., Mantel-Teeuwisse, A. K., Hidalgo‐Simon, A., Egberts, T. C. G., Leufkens, H. G. M., & Bruin, M. L. D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.207 · Cited by 22
Cited by
Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0079-y · Cited by 953
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N. L., Massey, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011124 · Cited by 813
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
Metadata
- Authors
- Tandan, R., Hehir, M. K., Waheed, W., & Howard, D. B.
- Venue
- Muscle & Nerve
- Publisher
- Wiley
- Published
- 2017-03-21
- Volume
- 56
- Issue
- 2
- Pages
- 185-196
- ISSN
- 0148-639X (ISSN-L)
- OpenAlex
- W2586254189
- Cited by
- 275
- References
- 38
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.